Saturday, December 11, 2021 12:32:40 PM
The reason they are refusing to release the data is because it is bad. That's right, the data is bad. I mean, could it not be more obvious? What else could they possibly be (not) doing to make people realize this is a failed trial, and that you can't change endpoints after conducting a trial for 16 years, and you can't use historical controls to make valid comparisons? It is a failure. That is why they haven't even bothered to update the trial register. Failure is BY FAR the most likely and plausible explanation for why we haven't seen the data.
They are waiting on certification for Sawston to announce it. That makes perfect sense. You don't want to announce the trial failed now, before you get certification, because everything could collapse. But if you wait until you have certification, then you have something to fall back on (at least for Advent) and it is highly unlikely that everything would collapse.
Unfortunately, when that happens, I think there's a good chance NWBO shareholders will be left on the sideline as Advent ramps up into a full-scale manufacturing operation - like Cognate did before it sold for $800 million. Believe me when I tell you that sale got her attention. When she saw that Cognate sold for $800 million just a couple years after she had sold it for a lot less, I think a light bulb went off in her head. She doesn't need this failed vaccine anymore, and she doesn't need NWBO shareholders anymore, either.
Recent NWBO News
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 10:04:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:31:35 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/16/2023 10:11:54 PM
- Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia • InvestorsHub NewsWire • 11/15/2023 12:19:31 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:30:39 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 • InvestorsHub NewsWire • 11/09/2023 01:00:34 PM
- Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo • InvestorsHub NewsWire • 11/07/2023 12:29:43 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2023 08:36:14 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM